Oncology & Hematology

PAREXEL’s extensive experience and expertise in oncology and hematology can provide you with both strategic and practical solutions for your product development.  Our global team has recent and relevant experience with the class of investigational agent, the mechanism of action and specific indication to help you navigate your way through the complexities of the clinical development journey. Our ongoing relationships with key opinion leaders in the field, familiarity with the most appropriate investigative sites, understanding of the competitive environment, accumulation of knowledge from the development of other similar agents, and our ability to provide proactive solutions to potential issues will all help ensure that the pathway forward is as direct as possible. 

Specific strengths of our Oncology and Hematology experts include:

• Clinical experience in virtually all solid tumor and hematologic malignancies, including epidemiology, pathogenesis, diagnosis, prognosis, biomarkers, standard of care treatment, and state-of-the-art investigational therapies.
• A similar experience with a wide range of non-malignant hematologic disorders involving red cells, white blood cells, platelets, and coagulation factors.
• Extensive experience with medical feasibility studies, providing critical data about regions, countries, sites, and investigators, including local patterns of care, quality of care, and competing trials.
• Expertise managing complex oncology and hematology trials in Phase I-IV in every region.
• Proficiency in central review of medical imaging/clinical data.
• Experience in academic medicine, hospital-based clinical practice and clinical and laboratory research investigations and, in some cases, ongoing medical faculty positions at teaching hospitals.
• Active engagement in continuing medical education.
• Major commitment to internal oncology training for PAREXEL staff and experience in external oncology training for Sponsor’s oncology teams.
• Deep expertise in non-clinical and early drug development and regulatory consulting.
• Service on editorial boards of major oncology and hematology journals.
• Active participation in international professional organizations, including American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), European Society of Medical Oncology (ESMO), and European Cancer Conference (ECCO).

Key Materials

Readying Your Science for the Real World

Learn why drug development today is more than a process. It's a journey. Click here.